The Bayer Activities of Daily Living Scale (B-ADL)

Dementia and Geriatric Cognitive Disorders

Volumn 9, Issue SUPPL. 2, 1998, Pages 20-26

  Hindmarch, Ian ^a   Lehfeld, Hartmut ^b   De Jongh, Perry ^c   Erzigkeit, Hellmut ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c BAYER AG   (Germany)

Author keywords

Activities of daily living; Alzheimer's disease; B ADL; Dementia screening; Mild cognitive impairment; Therapy evaluation; Vascular dementia

Indexed keywords

ALZHEIMER DISEASE; CAREGIVER; COGNITIVE DEFECT; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DEMENTIA; HUMAN; MULTIINFARCT DEMENTIA; PATIENT MONITORING; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE;

EID: 0031842242     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051195     Document Type: Conference Paper

References (22)

1. Rubin EH, Morris C, Grant EA, Vendegna T: Very mild senile dementia of the Alzheimer type. I: Clinical assessment. Arch Neurology 1989;46:379-382.
2. Morris JC, McKeel DW, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L: Very mild Alzheimer's disease: Informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991;41: 469-478.
3. Curran S, Russell E, Burns A: Treatment of cognitive deficits in Alzheimer's disease. Prim Care Psychiatry 1997;3,151-161.
4. Jorm AF, Korten AE: Assessment of cognitive decline in the elderly by informant interview. Br J Psych 1988;152:209-213.
5. Committee for Proprietary Medicinal Products (CPMP): Note for guidance on medicinal products in the treatment of Alzheimer's disease. The European Agency for the Evaluation of Medicinal Products. London, Human Medicines Evaluation Unit, 1997.
6. Gauthier S, Bodick N, Erzigkeit H, Feldman H, Geldmacher DS, Huff J, Mohs R, Orgogozo JM, Rogers S: Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(suppl 3):6-7.
7. Leber P: Guidelines for the clinical evaluation of antidementia drugs. First draft. Rockville, Food and Drug Administration, 1990.
8. Clinical Research Working Group from the Pharmaceutical Industry on Dementia: Recommendations for clinical drug trials in dementia. Dementia 1990;1:292-295.
9. Poon LW: On the paradox of improving sensitivity of ADL scales for the detection of behavioural changes in early dementia. Int Psychogeriatr 1994;6:171-177.
10. Schmidt-Gollas N, Erzigkeit H: Ways of constructing a therapy sensitive scale for the assessment of ADL aspects in cognitively impaired elderly patients; in Bergener M, Belmaker R, Tropper H (eds): Pharmacotherapy for the elderly. Research and Implications. New York, Springer, 1993, pp 119-131.
11. Erzigkeit H, Overall JE, Stemmler M, Steinwachs KC, Lehfeld H, Hulla FW: Assessing behavioral changes in antidementia therapy: Perspectives of an international ADL-project; in Bergener M, Brocklehurst J, Finkel S (eds): Aging, Health, and Healing. New York, Springer, 1995, pp 359-374.
12. Finkel S, Bergener M, Stemmler M, Hulla F, Overall JE: The use of clinical experience to stage the severity of functional impairments in Alzheimer's disease. Hum Psychopharmacol 1996;11:439-449.
13. Lehfeld H, Reisberg B, Finkel S, Kanowski S, Wied V, Pittas J, Tsolaki M, Robert PH, Hulla F, Heininger K, Erzigkeit H: Informant-rated Activities-of-Daily-Living (ADL) Assessments: Results of a study of 141 items in the USA, Germany, Russia, and Greece from the International ADL Scale Development Project. Alzheimer Dis Assoc Disord 1997;11(suppl 4): S39-S44.
14. Reisberg B: The ADL-IS: History and Progress. Presentation at the eighth congress of the International Psychogeriatric Association (IPA). 1996, Jerusalem, Israel, August 17-22.
15. Barberger-Gateau P, Commenges D, Gagnon M, Letenneur L, Sauvel C, Dartigues JF: Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. J Am Geriatr Soc 1992;40:1129-1134.
16. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S, Alzheimer's Disease Cooperative Study: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord;11(suppl 2):S33-S39.
17. Lundin-Olsson I, Nyberg L, Gustafson Y: 'Stops walking when talking' as a predictor of falls in elderly people. Lancet 1997, 349:617.
18. Herberg KW, Steinwachs KC, Woelk H, Bernhardt T: Alltagskompetenz älterer Patienten wächst unter einer Therapie mit Nimodipin. Extrada Geriatrica 1997;3:20-25.
19. Heininger K, Keppel Hesselink JM: The role of the Bayer ADL-International Scale in the management of dementia patients. Presentation at the eighth congress of the International Psychogeriatric Association (IPA). 1996, Jerusalem, Israel, August 17-22.
20. Brislin RW: The wording and translation of research instruments; in Lonner W, Berry J (eds): Field methods in Cross-Cultural Research. Beverly Hills, Sage, 1986, pp 137-164.
21. Sartorius N, Kuyken W: Translation of health status instruments; in Orley J, Kuyken W (eds): Quality of Life Assessment in Health Care Settings. Berlin, Springer, 1994, pp 3-18.
22. Reisberg B, Ferris SH, deLeon MJ, Crook T: The Global Deterioration Scale for the assessment of primary degenerative dementia. Am J Psych 1982;139:1136-1139.